As indicated in step 1 of Figure 3, neoantigen identification starts with sequencing the tumour exome and optional RNA sequencing to identify the indels in microsatellite regions which are then analysed through computational modelling to predict the neoantigens that have the strongest binding affinity to the patients’ MHC molecules [77]. This evidence concerns the gene HLA-C and neoplasm.